TrialsgrambetaRCTs are beautiful

HORIZON-PFT

2007

Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly

In 7,765 postmenopausal women with osteoporosis, annual intravenous zoledronic acid 5 mg reduced new vertebral and hip fractures compared with placebo.

Result

Efficacy: New morphometric vertebral fractureRR 0.3 · P < 0.001

Below 1 favours annual intravenous zoledronic acid 5 mg, above 1 favours placebo.

Also reported: Hip fracture HR 0.59 (−41 %; p=0.002).

Original publication
Subtopic
Intravenous bisphosphonate
Design
Double-blind RCT, 3 yr
Relevance
Important: one of several pillars.
Source
Black DM, et al. N Engl J Med. 2007;356(18):1809-1822.doi 10.1056/NEJMoa067312

Discussion & critique

Established annual intravenous bisphosphonate dosing, the option for patients intolerant of oral therapy or with adherence concerns.

Discussed in podcasts